Skip to main content
60°
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich Pendulum
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
Classifieds
Place ad
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Community Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by ORIC Pharmaceuticals
ORIC Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operational Updates
August 12, 2024
From
ORIC Pharmaceuticals
Via
GlobeNewswire
Tickers
ORIC
ORIC Pharmaceuticals Expands Leadership Team with the Appointment of Keith Lui as Senior Vice President of Commercial and Medical Affairs
August 05, 2024
From
ORIC Pharmaceuticals
Via
GlobeNewswire
Tickers
ORIC
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
August 02, 2024
From
ORIC Pharmaceuticals
Via
GlobeNewswire
Tickers
ORIC
ORIC Pharmaceuticals Announces Multiple Clinical Collaborations with Strategic Partners to Support Ongoing Trial Evaluating ORIC-944 in Combination with AR Inhibitors for the Treatment of Prostate Cancer
July 16, 2024
From
ORIC Pharmaceuticals
Via
GlobeNewswire
Tickers
ORIC
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
July 05, 2024
From
ORIC Pharmaceuticals
Via
GlobeNewswire
Tickers
ORIC
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
June 07, 2024
From
ORIC Pharmaceuticals
Via
GlobeNewswire
Tickers
ORIC
ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences
May 29, 2024
From
ORIC Pharmaceuticals
Via
GlobeNewswire
Tickers
ORIC
ORIC Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational Updates
May 06, 2024
From
ORIC Pharmaceuticals
Via
GlobeNewswire
Tickers
ORIC
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
May 03, 2024
From
ORIC Pharmaceuticals
Via
GlobeNewswire
Tickers
ORIC
ORIC Pharmaceuticals Announces First Patients Dosed Across Three Expansion Cohorts in Phase 1b Trial of ORIC-114 in Patients with Mutated NSCLC
April 15, 2024
From
ORIC Pharmaceuticals
Via
GlobeNewswire
Tickers
ORIC
ORIC Pharmaceuticals Presents Preclinical Data on Two Programs at the 2024 American Association for Cancer Research (AACR) Annual Meeting
April 08, 2024
From
ORIC Pharmaceuticals
Via
GlobeNewswire
Tickers
ORIC
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
April 05, 2024
From
ORIC Pharmaceuticals
Via
GlobeNewswire
Tickers
ORIC
ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences
April 04, 2024
From
ORIC Pharmaceuticals
Via
GlobeNewswire
Tickers
ORIC
ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Updates
March 11, 2024
From
ORIC Pharmaceuticals
Via
GlobeNewswire
Tickers
ORIC
ORIC Pharmaceuticals to Present at the Leerink Partners Global Biopharma Conference
March 06, 2024
From
ORIC Pharmaceuticals
Via
GlobeNewswire
Tickers
ORIC
ORIC Pharmaceuticals Announces Multiple Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting
March 05, 2024
From
ORIC Pharmaceuticals
Via
GlobeNewswire
Tickers
ORIC
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
March 01, 2024
From
ORIC Pharmaceuticals
Via
GlobeNewswire
Tickers
ORIC
ORIC Pharmaceuticals to Participate in the Citi 2024 Virtual Oncology Leadership Summit
February 14, 2024
From
ORIC Pharmaceuticals
Via
GlobeNewswire
Tickers
ORIC
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
February 02, 2024
From
ORIC Pharmaceuticals
Via
GlobeNewswire
Tickers
ORIC
ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences
January 31, 2024
From
ORIC Pharmaceuticals
Via
GlobeNewswire
Tickers
ORIC
ORIC Pharmaceuticals Announces $125 Million Private Placement Financing
January 22, 2024
From
ORIC Pharmaceuticals
Via
GlobeNewswire
Tickers
ORIC
ORIC Pharmaceuticals Provides Initial Phase 1b Data for ORIC-944, Operational Highlights for 2023, and Anticipated Upcoming Milestones
January 08, 2024
From
ORIC Pharmaceuticals
Via
GlobeNewswire
Tickers
ORIC
ORIC Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 02, 2024
From
ORIC Pharmaceuticals
Via
GlobeNewswire
Tickers
ORIC
Initial Phase 1 Dose Escalation Data for ORIC-533 in Relapsed/Refractory Multiple Myeloma Demonstrates Clinical Activity and Strong Safety Profile Supporting Potential for Combination Development
December 11, 2023
From
ORIC Pharmaceuticals
Via
GlobeNewswire
Tickers
ORIC
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
December 01, 2023
From
ORIC Pharmaceuticals
Via
GlobeNewswire
Tickers
ORIC
ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences
November 09, 2023
From
ORIC Pharmaceuticals
Via
GlobeNewswire
Tickers
ORIC
ORIC Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operational Updates
November 06, 2023
From
ORIC Pharmaceuticals
Via
GlobeNewswire
Tickers
ORIC
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
November 03, 2023
From
ORIC Pharmaceuticals
Via
GlobeNewswire
Tickers
ORIC
ORIC Pharmaceuticals to Present Initial Phase 1b Clinical Data for ORIC-533 in Multiple Myeloma at the 65th American Society of Hematology (ASH) Annual Meeting
November 02, 2023
From
ORIC Pharmaceuticals
Via
GlobeNewswire
Tickers
ORIC
Initial Phase 1 Dose Escalation Data of ORIC-114 in Patients with EGFR and HER2 Exon 20 Mutations Demonstrates Potential Best-In-Class Profile
October 21, 2023
From
ORIC Pharmaceuticals
Via
GlobeNewswire
Tickers
ORIC
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.